<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000643597"><TermName>anti-TRAIL R2 mAb HGS-ETR2</TermName><TermPronunciation>(AN-tee ...)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL-R2 on the surface of some tumor cells, which may kill the tumor cells. Anti-TRAIL R2 mAb HGS-ETR2 is a type of monoclonal antibody. Also called HGS-ETR2 and lexatumumab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000725784" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anti-TRAIL R2 mAb HGS-ETR2&quot;" language="en" id="_3"/><MediaLink ref="CDR0000725783" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;mAb HGS-ETR2 anti-TRAIL R2&quot;" language="es" id="_4"/><SpanishTermName>mAb HGS-ETR2 anti-TRAIL R2</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. Se une con una proteína que se llama TRAIL-R2 de la superficie de algunas células tumorales, lo que podría destruir estas células. El mAb HGS-ETR2 anti-TRAIL R2 es un tipo de anticuerpo monoclonal. También se llama HGS-ETR2 y lexatumumab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-05-19</DateFirstPublished><DateLastModified>2009-05-08</DateLastModified></GlossaryTerm>
